Use of aloperine in the preparation of drugs for the prevention and treatment of pulmonary arterial hypertension

A technology of pulmonary arterial hypertension and aloperine, which is applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., to achieve the effects of reducing hypertrophy, inhibiting hypertrophy, and reducing pulmonary artery pressure

Active Publication Date: 2019-06-04
NINGXIA MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether it has an inhibitory effect on the occurrence and development of pulmonary hypertension, and whether its mechanism of action is related to anti-oxidative stress has not yet been elucidated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of aloperine in the preparation of drugs for the prevention and treatment of pulmonary arterial hypertension
  • Use of aloperine in the preparation of drugs for the prevention and treatment of pulmonary arterial hypertension
  • Use of aloperine in the preparation of drugs for the prevention and treatment of pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Aloperine is used as a drug for the treatment of pulmonary arterial hypertension, and the structural formula of aloperine is as shown in formula (1):

[0035]

[0036] Wherein, a single application dose of aloperine is 25 mg / kg for rats, and the dosage form of the medicine is an oral dosage form.

Embodiment 2

[0038] Aloperine is used as a drug for the treatment of pulmonary arterial hypertension, and the structural formula of aloperine is as shown in formula (1):

[0039]

[0040] Wherein, a single application dose of aloperine is 50 mg / kg for rats, and the dosage form of the medicine is an oral dosage form.

Embodiment 3

[0042] Aloperine is used as a drug for the treatment of pulmonary arterial hypertension, and the structural formula of aloperine is as shown in formula (1):

[0043]

[0044] Wherein, a single application dose of aloperine is 100 mg / kg for rats, and the dosage form of the medicine is an oral dosage form.

[0045] The effect of embodiment 1-3 can be confirmed by following experiment and result thereof:

[0046] 1. Experimental materials

[0047] 1.1 Animal handling

[0048] 180-220g male SD rats were purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: NCXK (Ning) 2015-0005. Feeding conditions include standard feed, tap water, room temperature maintained at (21±2)°C, humidity 50-60%, and daily light and dark times of 12 hours each. Before the experiment, the animals were placed in the experimental environment for 7 days to adapt.

[0049] 1.2 Experimental drugs and instruments

[0050] Aloperine (purchased from N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of aloperine (ALO) to preparation of a medicine for preventing and curing pulmonary arterial hypertension. A rat pulmonary hypertension model is established to explore the protection effect and mechanism of aloperine on rat pulmonary hypertension. The experiment shows that after the pulmonary hypertension model is established, the aloperine can remarkably improve the hemodynamic parameter, the right ventricular hypertrophy index, the lung index, and the echocardiographic parameter, the pathological injury of pulmonary arterioles is improved, the antioxidant ability of a lung tissue is improved, and the malondialdehyde content and the level of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-2 and NOX-4 in the lung tissue are reduced. The aloperine has the effects of inhibiting the development of pulmonary arterial hypertension, oxidative stress and overexpression of NOX-2 and NOX-4.

Description

technical field [0001] The present invention relates to the application of aloperine, in particular to the application of aloperine in the preparation of drugs for prevention and treatment of pulmonary arterial hypertension. Background technique [0002] Pulmonary hypertension is a group of clinical syndromes characterized by a progressive increase in pulmonary artery pressure and pulmonary vascular resistance, resulting in increased right ventricular afterload and decreased pulmonary blood flow. Continuously increased pulmonary vascular resistance can lead to right ventricular failure and eventually cause death. Studies have found that the pathogenesis of pulmonary hypertension includes pulmonary vascular endothelial dysfunction, pulmonary inflammatory response, pulmonary artery vasoconstriction, pulmonary vascular wall remodeling, and imbalance between smooth muscle cell proliferation and apoptosis. As far as the current drugs for the treatment of pulmonary hypertension a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4748A61P11/00A61P9/12
CPCA61K31/4748
Inventor 周茹吴凡余建强姚婉霞马鹏生
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products